Tenax Therapeutics announced that the FDA has reviewed and cleared the company’s Investigational New Drug – IND – Application for TNX-103 oral levosimendan for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction – PH-HFpEF -, enabling Tenax to proceed with the first of two Phase 3 studies. The LEVEL Study is expected to launch in Q4 2023.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TENX: